MPWT
SYRE icon

MassMutual Private Wealth & Trust’s Spyre Therapeutics SYRE Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$219 – 2491
2026
Q1 		$151 Buy
+3
New +$113 ﹤0.01% 2341

Other funds holding SYRE

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

MassMutual Private Wealth & Trust's SYRE Position: Q2 2026 in Review

MassMutual Private Wealth & Trust sold out of Spyre Therapeutics (SYRE) in Q2 2026, closing a stake of 3 shares — an estimated $219 sold.

MassMutual Private Wealth & Trust first reported a position in SYRE in Q1 2026 and held it in 1 quarter. The position peaked at $151 in Q1 2026. 33 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • MassMutual Private Wealth & Trust reported no remaining Spyre Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MassMutual Private Wealth & Trust sold 3 Spyre Therapeutics shares in Q2 2026, an estimated $219.
  • MassMutual Private Wealth & Trust first reported a position in Spyre Therapeutics in Q1 2026 and held it in 1 quarter.
  • MassMutual Private Wealth & Trust's Spyre Therapeutics position peaked at $151 in Q1 2026.
  • 33 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.